Table 1.
Subject demographic information.
| Before | During | All | |
|---|---|---|---|
| Sex (M/F) | 2/4 | 4/2 | 6/6 |
| Age (years) | 47.0 ± 13.6 | 55.8 ± 7.4 | 51.4 ± 11.4 |
| Height (cm) | 160.4 ± 5.4 | 177.4 ± 10.8 | 168.9 ± 12.0 |
| Weight (kg) | 66.7 ± 13.4 | 86.1 ± 22.2 | 76.4 ± 20.2 |
| Time since diagnosis (years) | 17.7 ± 12.9 | 17.5 ± 12.7 | 17.6 ± 12.2 |
| PDDS | 2.7 ± 1.4 | 3.8 ± 1.2 | 3.3 ± 1.4 |
| FSS | 4.2 ± 2.3 | 5.3 ± 0.5 | 4.8 ± 1.7 |
| Medications | |||
| DMT (%) | 66.7 | 66.7 | 66.7 |
| Others (%) | 16.7 | 33.3 | 25.0 |
Data are mean ± SD. Note: PDDS, Patient-Determined Disease Steps; FSS, Fatigue Severity Scale; DMT, disease modifying therapies (Aubagio, Ocrevus, Tecfidera, or Copaxone); Others, fatigue (Modafinil, Adderall), spasticity (Baclofen), or walking (Ampryra). FSS served as the covariate in the statistical analysis. Medications are percentage of subjects taking either DMT or other MS-related drugs.